Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Cancer Chemotherapy and Pharmacology|January 27, 2016
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancerSu Jin Heo, Inkyung Jung, Choong-Kun Lee, et al.
Cancer Research and Treatment|July 21, 2023
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH TrialKyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, et al.
Therapeutic Advances in Medical Oncology|March 7, 2022
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical modelsSun Min Lim, San-Duk Yang, Sangbin Lim, et al.
Oncoimmunology|June 26, 2024
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, et al.
Yonsei Medical Journal|February 10, 2012
Treatment outcome of patients with anaplastic thyroid cancer: a single center experienceSun Min Lim, Sang-Joon Shin, Woong Youn Chung, et al.
The Journal of Molecular Diagnostics : JMD|January 15, 2014
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancerMaruja E Lira, Yoon-La Choi, Sun Min Lim, et al.
Annals of Nuclear Medicine|February 4, 2016
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinomaSun Min Lim, Hyunki Kim, Beodeul Kang, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinomaSun Min Lim, Jae Woo Choi, Min Hee Hong, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2026
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancerByoung Chul Cho, Sun Min Lim, Sang Hoon Lee, et al.
Pageof 14